Literature DB >> 30229271

Background parenchymal enhancement in pregnancy-associated breast cancer: a hindrance to diagnosis?

Jana Taron1, Sabrina Fleischer2, Heike Preibsch2, Konstantin Nikolaou2, Ines Gruber3, Sonja Bahrs2.   

Abstract

PURPOSE: The purpose of this study is to investigate the detectability of pregnancy-associated breast cancer (PABC) in lactating glandular tissue on magnetic resonance imaging (MRI) by using pre- and post-contrast acquisitions and their derived postprocessed images and compare these results to ultrasound (US) and mammography (MG).
MATERIALS AND METHODS: We reviewed the electronic database for women with PABC and existing breast MRI. MR images (T2-weighted short inversion-recovery sequence [STIR], dynamic contrast-enhanced T1-weighted gradient echo sequence and postprocessed subtraction images [early post-contrast minus pre-contrast]) were retrospectively evaluated (image quality, parenchymal/tumour enhancement kintetics, tumour size and additional lesions). Supplemental subtraction images (latest post-contrast minus early post-contrast) to reduce plateau enhancement were additionally calculated and tumour conspicuity and size were measured. Findings were compared to US and MG reports.
RESULTS: Nineteen patients (range 27-42 years) were included. Background parenchymal enhancement (BPE) was minimal (n=1), mild (n=3), moderate (n=7) and marked (n=8) with kinetics measured plateau (n=8), continuous (n=10) and not quantifiable (n=1). Tumour kinetics presented wash-out (n=17) and plateau (n=2). Eighteen of nineteen tumours were identified on the supplemental subtraction images. All tumours were visible on US; 12/19 were visible on MG (63.2%). MRI detected additional malignant lesions in two patients.
CONCLUSION: Despite high BPE of the lactating breast, MRI securely detects carcinomas and identifies satellite lesions. By using supplemental subtraction images, background enhancement can be eliminated to facilitate diagnosis. US remains a reliable diagnostic tool, but additional MRI is recommended to rule out satellite/contralateral lesions. MG interpretations can be difficult due to high parenchymal density. KEY POINTS: • Despite high background enhancement, MRI of the breast confidently detects carcinomas and identifies further lesions in the lactating breast. • By using supplemental subtraction images, background enhancement in the lactating breast can be eliminated to facilitate diagnosis. • US remains a reliable diagnostic tool. Mammography can be limited due to extremely dense breast tissue related to lactation.

Entities:  

Keywords:  Breast cancer; Magnetic resonance imaging; Pregnancy

Mesh:

Year:  2018        PMID: 30229271     DOI: 10.1007/s00330-018-5721-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  New subtraction algorithms for evaluation of lesions on dynamic contrast-enhanced MR mammography.

Authors:  Byung Gil Choi; Hak Hee Kim; Euy Neyng Kim; Bum-soo Kim; Ji-Youn Han; Seung-Schik Yoo; Seog Hee Park
Journal:  Eur Radiol       Date:  2002-04-30       Impact factor: 5.315

Review 2.  The lactating breast: MRI findings and literature review.

Authors:  Anjali C Talele; Priscilla J Slanetz; Whitney B Edmister; Eren D Yeh; Daniel B Kopans
Journal:  Breast J       Date:  2003 May-Jun       Impact factor: 2.431

Review 3.  Pregnancy-associated breast cancer: spectrum of imaging appearances.

Authors:  A P Ayyappan; S Kulkarni; P Crystal
Journal:  Br J Radiol       Date:  2010-03-24       Impact factor: 3.039

4.  Three-phase dynamic breast magnetic resonance imaging with two-way subtraction.

Authors:  Nami Choi; Boo-Kyung Han; Yeon Hyeon Choe; Hye Sung Kim
Journal:  J Comput Assist Tomogr       Date:  2005 Nov-Dec       Impact factor: 1.826

Review 5.  Multidisciplinary management of breast cancer concurrent with pregnancy.

Authors:  Angela J Keleher; Richard L Theriault; Karin M Gwyn; Kelly K Hunt; Carol B Stelling; S Eva Singletary; Frederick C Ames; Thomas A Buchholz; Aysegul A Sahin; Henry M Kuerer
Journal:  J Am Coll Surg       Date:  2002-01       Impact factor: 6.113

6.  Optimal timing of breast MRI examinations for premenopausal women who do not have a normal menstrual cycle.

Authors:  Richard L Ellis
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

7.  The lactating breast: contrast-enhanced MR imaging of normal tissue and cancer.

Authors:  Leandro A Espinosa; Bruce L Daniel; Logi Vidarsson; Marowan Zakhour; Debra M Ikeda; Robert J Herfkens
Journal:  Radiology       Date:  2005-11       Impact factor: 11.105

8.  Imaging and Management of Breast Masses During Pregnancy and Lactation.

Authors:  Jacquelyn P. Hogge; Ellen Shaw De Paredes; Colette M. Magnant; Janice Lage
Journal:  Breast J       Date:  1999-07       Impact factor: 2.431

Review 9.  Radiologic evaluation of breast disorders related to pregnancy and lactation.

Authors:  Josep M Sabate; Montse Clotet; Sofia Torrubia; Antonio Gomez; Ruben Guerrero; Pilar de las Heras; Enrique Lerma
Journal:  Radiographics       Date:  2007-10       Impact factor: 5.333

10.  Prognosis of pregnancy-associated breast cancer.

Authors:  J A Petrek; R Dukoff; A Rogatko
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

View more
  2 in total

1.  Breast MRI during lactation: effects on tumor conspicuity using dynamic contrast-enhanced (DCE) in comparison with diffusion tensor imaging (DTI) parametric maps.

Authors:  Noam Nissan; Tanir Allweis; Tehillah Menes; Asia Brodsky; Shani Paluch-Shimon; Ilana Haas; Orit Golan; Yaheli Miller; Hani Barlev; Einat Carmon; Malka Brodsky; Debbie Anaby; Philip Lawson; Osnat Halshtok-Neiman; Anat Shalmon; Michael Gotlieb; Renata Faermann; Eli Konen; Miri Sklair-Levy
Journal:  Eur Radiol       Date:  2019-09-16       Impact factor: 5.315

Review 2.  Breast MRI during pregnancy and lactation: clinical challenges and technical advances.

Authors:  Noam Nissan; Ethan Bauer; Efi Efraim Moss Massasa; Miri Sklair-Levy
Journal:  Insights Imaging       Date:  2022-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.